Audited Financial Results for the half year and year ended March 31, 2206
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 03 Jun 2026, 09:27 PM IST · BSE ID: 95ae9a72-c1da-4f18-94a5-782d22e950bc
View Original BSE Filing (PDF)
💡
In Simple Terms
Dr Lalchandani Labs announced its yearly financial results, showing a loss for the latest half-year and a new agency to monitor funds.
🤖 AI Summary
- Dr Lalchandani Labs Ltd. approved audited standalone financial results for the year ended March 31, 2026.
- Profit/(Loss) for the half year ended March 31, 2026, was (13.15) INR Lacs.
- Total Revenue from Operations for the year ended March 31, 2026, stood at 441.80 INR Lacs.
- M/s. Brickwork Ratings India Private Limited appointed as Monitoring Agency for Rights Issue Proceeds.
- The company recorded a One Time Settlement gain of 61.08 INR Lacs for unsecured loans.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Profit/ (Loss) for the half year ended Mar 31, 2026
(13.15) INR Lacs
Total Revenue from Operations for the year ended Mar 31, 2026
441.80 INR Lacs
14.80
Total Expenses for the year ended Mar 31, 2026
470.05 INR Lacs
12.44
Net Cash Flows From Operating Activities for the year ended Mar 31, 2026
(76.46) INR Lacs
🏢 How This Affects the Company
The company's revenue from operations increased to 441.80 INR Lacs for the year ended March 31, 2026, indicating growth in core business activities.
The company reported a Profit/(Loss) for the period of (13.15) INR Lacs for the half year ended March 31, 2026, reflecting a financial loss. Net cash flows from operating activities were (76.46) INR Lacs for the year ended March 31, 2026.
The appointment of M/s. Brickwork Ratings India Private Limited as Monitoring Agency affects compliance and oversight of Rights Issue Proceeds utilization.
The auditors' report highlighted concerns regarding non-performing assets, defaults on principal and interest payments, and non-provision for doubtful debts, indicating elevated financial and operational risks. Non-payment of statutory dues for PF, ESI, TDS was also noted.
👥 What This Means For Shareholders
✅
Action Required
No direct action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported financial performance, including the Profit/(Loss) of (13.15) INR Lacs for the half year. The audit qualifications highlight potential risks to the company's financial health.
🔍
Management Signal
The board's approval of the audited results and appointment of a monitoring agency indicates an adherence to regulatory compliance and oversight of financial operations, despite adverse findings.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — review financial performance and auditor comments.
Monitoring Agency Report — assess utilization of Rights Issue Proceeds.
Updates on non-performing assets and resolution of auditor qualifications.
HIGH RISK
Significant audit qualifications, negative operating cash flows, and defaults on loans indicate high financial risk.
💡 Investor Takeaway
Dr Lalchandani Labs Ltd. reported a Profit/(Loss) of (13.15) INR Lacs for the half year ended March 31, 2026, with full-year Total Revenue from Operations at 441.80 INR Lacs. The auditors' report contained qualifications regarding non-performing assets, defaults, and statutory dues.
⚖️ Strengths & Concerns
✅ Positives
- Total Revenue from Operations increased to 441.80 INR Lacs for the year ended March 31, 2026, from 384.87 INR Lacs in the prior year.
- The company recorded a One Time Settlement gain of 61.08 INR Lacs from unsecured loans with various Banks/NBFC's, reducing debt obligations.
⚠️ Concerns
- Profit/(Loss) for the period was (13.15) INR Lacs for the half year ended March 31, 2026, indicating a loss-making period.
- Net cash flows from operating activities were negative (76.46) INR Lacs for the year ended March 31, 2026, suggesting cash burn from core operations.
📅 Company Track Record
No previous filings were found for Dr Lalchandani Labs Ltd. in the immediate context. This filing represents a primary public disclosure of its audited financial results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Dr Lalchandani Labs Ltd.'s Profit/(Loss) for the half year ended March 31, 2026?
Dr Lalchandani Labs Ltd. reported a Profit/(Loss) of (13.15) INR Lacs for the half year ended March 31, 2026.
What was Dr Lalchandani Labs Ltd.'s Total Revenue from Operations for the year ended March 31, 2026?
The Total Revenue from Operations for Dr Lalchandani Labs Ltd. for the year ended March 31, 2026, was 441.80 INR Lacs.
Which agency was appointed to monitor Rights Issue Proceeds for Dr Lalchandani Labs Ltd.?
M/s. Brickwork Ratings India Private Limited was appointed as Monitoring Agency for Rights Issue Proceeds for Dr Lalchandani Labs Ltd.
What was the One Time Settlement gain recorded by Dr Lalchandani Labs Ltd.?
Dr Lalchandani Labs Ltd. recorded a One Time Settlement gain of 61.08 INR Lacs for its unsecured loans.
What were Dr Lalchandani Labs Ltd.'s Net Cash Flows From Operating Activities for the year ended March 31, 2026?
Dr Lalchandani Labs Ltd.'s Net Cash Flows From Operating Activities for the year ended March 31, 2026, were (76.46) INR Lacs.
Questions based on this BSE filing only. For information purposes.